共 67 条
[1]
Hanna N(2004)Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589-1597
[2]
Shepherd FA(2013)PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer J Clin Oncol 31 2895-2902
[3]
Fossella FV(2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129-2139
[4]
Paz-Ares LG(2004)EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497-1500
[5]
de Marinis F(2013)Treating patients with EGFR-sensitizing mutations: first line or second line–is there a difference? J Clin Oncol 31 1081-1088
[6]
Dediu M(2014)Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii27-iii39
[7]
Lynch TJ(2012)The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation Curr Med Chem 19 3337-3352
[8]
Bell DW(2011)Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2866-2874
[9]
Sordella R(2013)Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Ann Oncol 24 54-59
[10]
Paez JG(2014)The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial Clin Cancer Res 20 2001-2010